A choice for your patients in need
of ankle or
hindfoot fusion
According to the U.S. Census Bureau, there are about 78.21 million
baby boomers. This is a generation that is media-savvy and is willing
and able to look at their healthcare options. They are also of
an age where foot and ankle problems, particularly those associated
with osteoarthritis, are most likely coming into evidence.
Once they have exhausted their conservative care options, they
will be looking to you to tell them about their options. All their
options.
If surgery is their best option, give them an alternative
GEM OS®1 is an investigational
device that may be of benefit to your patients who are candidates
for hindfoot or ankle joint fusion (e.g. subtalar fusion, calcaneocuboid
fusion, talonavicular fusion, triple arthrodesis or double fusions). GEM
OS1 is a fully synthetic material intended to obviate the
need for autograft in hindfoot or ankle fusion procedures.
GEM OS1 is a combination of a protein found naturally
in the body and a synthetic material, both of which have been previously
approved by the FDA. This product is intended to promote new bone
formation and enhance healing at the affected area in the ankle
or hindfoot. This material obviates for harvesting autologous bone;
thereby sparring patients the pain and potential problems associated
with additional surgery.
The Foot and Ankle Fusion Study is currently permitted to enroll
patients at up to 28 sites throughout the U.S. Talk to your patients.
Find out if they may be interested in participating in this potentially
beneficial pivotal trial.
If you have any questions or feel you have patients who may
benefit from this study, call the nurse-staffed information line 1-866-921-6998 Mon–Thurs.,
7 am–7 pm and Friday, 7 am–6 pm, CST.
1
|
